Ventriculoperitoneal (VP) Shunt Placement

Treatment for Neural tube defects

Typical Dosage: N/A (surgical procedure)

Effectiveness
90%
Safety Score
55%
Clinical Trials
500
Participants
100K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
N/A (surgical procedure)
Time to Effect
Immediate
Treatment Duration
Lifetime (requires ongoing management and potential revisions)
Evidence Quality
HIGH
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,500
Side Effect Mgmt:$5,000
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$48,947.37
Ventriculoperitoneal (VP) Shunt Placement Outcomes

for Neural tube defects

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Shunt malfunction (occlusion, disconnection)
+35%
Shunt infection
+10%
Overdrainage (slit ventricle syndrome)
+7%
Seizures
+7%

Sources:

researchgate.net
nih.gov
wikipedia.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov